Cemsidomide demonstrated a 50% ORR at 100 μg, with one patient achieving a complete response and no detectable disease. The phase 1 study's dose-escalation phase is complete, and the 100 μg dose is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback